This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0018594493 Reproduction Date:
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
M: VAS
anat (a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
noco/syva/cong/lyvd/tumr, sysi/epon, injr
proc, drug (C2s+n/3/4/5/7/8/9)
Vasopressin, Vasopressin receptor, Orphan receptor, Cholecystokinin, Α-msh
Tolvaptan, Conivaptan, Lixivaptan, Relcovaptan, Demeclocycline, Arginine vasopressin receptor 1A